A Phase 3 interventional study of Aripiprazole in Adolescent Schizophrenia and Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 101 sites in 13 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-02-08.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Mania with a site in United States — 5 open to participants now, 5 under way, 4 of them phase 3. Mania · United States.
Among the 94 studies in Mania with a site in United States, this one is the 4th largest by enrollment of the 88 interventional ones that give a count, is one of 9 that started in 2010, is one of 32 in phase 3, and was the 68th registered.
167 studies on the registry are indexed under Mania; 14 are open to participants now.
Browse Mania studies →5 of the 94 studies in Mania with a site in United States are open now. Recruiting first, the newest first:
Neurocrine Biosciences · Sites in United States
Ages 18–65
Bristol-Myers Squibb · Sites in United States, Argentina, Bulgaria and 10 more countries
Ages 18–65
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 17 more countries
Ages 18–65
Bristol-Myers Squibb · Sites in United States, China, Croatia and 8 more countries
Ages 18–65
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 6 more countries
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Mania studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 20 · Phase 3 33 · Phase 4 27
First in 1991; this study’s year is marked. 9 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 524 is above the median of 89 across 139 interventional studies indexed under Mania.
Median enrollment 83 across the 88 interventional studies, 155 across the 6 observational. Of the 87 that completed or were terminated, 40 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 94 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 8 studies filed under Mania — fewer than ten, so there is no comparison to draw.
1 of the studies in Mania with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07140913Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine | 2027-06-28 |
Add it to your calendar (.ics) → With an account.
Among the 94 studies in Mania with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label study consisting of a screening period, a conversion/titration phase (Phase 1), an open-label treatment phase (Phase 2), and a follow-up period.
The study will enroll new subjects (hereafter referred as "de novo" subjects) with schizophrenia, or bipolar I disorder, manic or mixed episode with or without psychotic features, and rollover subjects with schizophrenia from 31-09-266 (hereafter referred to as "Study 266"). All de novo subjects must enter the screening period of the study. Subjects who are screened and are not required to go through Phase 1 will complete a Phase 2 baseline visit prior to their participation in Phase 2.
Study Design: Treatment, Single Group Assignment, Open Label, Active Control, Safety/Efficacy Study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
Drug: Aripiprazole
Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg) pill taken orally once per day
Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a participant or participant enrolled in a clinical trial and which did not necessarily have a causal relationship with the study medication. A treatment emergent adverse event (TEAE) was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study medication, whether or not considered to have a causal relationship with the study medication. A serious-AE or reaction was any untoward occurrence that, at any dose, was fatal, life-threatening, required inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was any other medically significant event that, based on appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the outcomes listed above.
Time frame: Adverse events were recorded from the time of the informed consent was signed throughout the 24 month treatment period until the follow-up visit 30 (± 3) days after the end of trial.
Incidence of Laboratory Values of Potential Clinical Relevance
The laboratory values were one of the parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria. Abnormal laboratory values in participants were reported as SAE/AEs and are reported in the SAE/other AE section of this report.
Time frame: Baseline to Month 24
Incidence of Physical Examination Findings of Potential Clinical Relevance
The physical examination evaluation was one of the parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in the following body systems: head, ears, eyes, nose, and throat; thorax; abdomen; urogenital; extremities; neurological; and skin and mucosae.
Time frame: Baseline to Month 24
Incidence of Vital Signs of Potential Clinical Relevance
Vital signs are taken at Baseline, Weeks 1, 2, 3, 4, 6, 8, and Months 3, 4, 6, 9, 12, 15, 18, 21, 24 of Phase 2 (Visits beyond Month 12 only for de novo subjects). Assessments included orthostatic (supine and standing) blood pressure (BP), heart rate and body temperature. Incidence of TEAEs of potential clinical relevance included abnormal values in heart rate, systolic and diastolic blood pressure, respiratory rate and weight that were identified based on pre-defined criteria. Abnormal vital signs in participants were reported as SAE/AEs and are reported in the SAE/other AE section of this report.
Time frame: Baseline to Month 24
Mean Change From Baseline by Week in Abnormal Involuntary Movement Scale (AIMS)
The AIMS Scale was an extrapyramidal symptoms (EPS) rating scale. The AIMS is a 12 item scale. The first 10 items e.g. facial and oral movements (items 1-4), extremity movements (items 5 and 6), trunk movements (item 7), investigators global assessment of dyskinesia (items 8 to 10). The first 10 items are rated from 0 to 4 (0=best, 4=worst). Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28.
Time frame: Baseline to Month 24
Mean Change From Baseline by Week in Simpson-Angus Scale (SAS) Total Score
The SAS is a rating scale used to measure EPS. The SAS scale consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia), with each item rated from 0 to 4, with 0 being normal and 4 being the worst. The SAS Total score is sum of ratings for all 10 items, with possible Total scores from 0 to 40.
Time frame: Baseline to Month 24
Mean Change From Baseline by Week in Barnes Akathisia Rating Scale (BARS) Score
The BARS was an EPS rating scale. The BARS was used to assess the presence and severity of akathisia. This scale consists of 4 items. Only the 4th item, the Global Clinical Assessment of Akathisia, was evaluated in this trial. This item is rated on a 6 point scale, with 0 being best (absent) and 5 being worst (severe akathisia).
Time frame: Baseline to Month 24
Number of Participants With Cognitive Impairment for Each New York Assessment for Adverse Cognitive Effects of Neuropsychiatric Treatment (NY-AACENT)
The NY-AACENT is not a validated scale. It was included in this trial because of concerns that regulatory authorities (the European Committee for Medicinal Products for Human Use \[CHMP\] and the Paediatric Sub-Committee of the European Medicinal Agency \[PDCO\]) had regarding drug induced cognitive impairment. No validated scale addressing these issues was available at the time of the trial. The NY-AACENT was used to detect changes in cognitive function subsequent to pharmacological or similar treatments for neurological or psychiatric problems. It was specifically designed to be used in pediatric populations (ages 12 to 17), but could have been utilized with other age groups, as appropriate.
Time frame: Baseline to Month 24
Baseline and Post-Baseline Tanner Staging
Tanner staging was completed together with the physical examination by the same trial-affiliated clinician in the most inconspicuous manner for the participant as possible. Tanner staging assessment consisted of 2 domains (pubic hair and breast development) for girls and 3 domains (pubic hair, penis development, and testes development) for boys. A participant who reached Stage 5 (both in pubic hair and genitalia) did not need to continue with Tanner Staging assessment and the Tanner Staging scales of this participant were imputed as 5 for all of the following scheduled time points up to and including the completion visit/ET visit. The clinician arrived at a single score summarizing the domains (not individual domain scores) when evaluating the participant. The total shift data for last visit is presented below.
Time frame: Baseline to Last Visit
Mean Change From Baseline for Columbia-Suicide Severity Rating Scale (C-SSRS) in Suicidal Ideation Intensity Total Score
Suicidality was defined as reporting at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any type of suicidal behaviors (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). Suicidal ideation was defined as reporting any type of suicidal ideation. The suicidal ideation intensity total score is the sum of intensity scores of 5 items (frequency, duration, controllability, deterrents, and reasons for ideation). The score of each intensity item ranges from 0 (none) to 5 (worst) which leads to the range of the total score from 0 to 25. A missing score of any item resulted in a missing total score. If no suicidal ideation was reported, a score of 0 was given to the intensity scale.
Time frame: Baseline to Month 24
Incidence of Suicidality, Suicidal Behavior and Suicidal Ideation
Suicidality was defined as reporting at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any type of suicidal behaviors (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). Suicidal ideation was defined as reporting any type of suicidal ideation. The below reported N value is the number of participants with specified suicidal ideation/behavior at the given time point.
Time frame: Baseline to Month 24
Percentage of Participants Who Discontinued Due to All Adverse Events
The percentage of participants who discontinued due to all causes other than sponsor terminating the trial was measured from the date of entering the open-label treatment phase to the date of ET for discontinued participants in the open-label treatment phase (ie, time to discontinuation = date of discontinuation \[or date of completion for completed participants\] - date of participant entering the open-label treatment phase + 1). If the participants completed the trial or were discontinued due to the sponsor terminating the trial, they were censored at the time of completion or trial termination, respectively.
Time frame: Baseline to Month 24
Mean Change From Baseline in Positive and Negative Symptoms Score (PANSS) Total Score
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
Time frame: Baseline to Month 24
Mean Change From Baseline in PANSS Positive Subscale Score
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).
Time frame: Baseline to Month 24
Mean Change From Baseline in PANSS Negative Subscale Score
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).
Time frame: Baseline to Month 24
Mean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score
The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
Time frame: Baseline to Month 24
Mean Change in Clinical Global Impression-Improvement (CGI-I) Score
The efficacy of trial medication were rated for each participant using the CGI-I scale. The study physician must rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at baseline. Response choices include: 0 = not assessed; 1 =very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 =minimally worse; 6 = much worse; and 7 = very much worse.
Time frame: Baseline to Month 24
Mean Change From Baseline in Young Mania Rating Scale (YMRS) Score
The YMRS consists of 11 items assessing the core symptoms of mania and was used to assess participants with bipolar I disorder, manic and mixed episodes with or without psychotic features: elevated mood, increased motor activity - energy, sexual interest, sleep, irritability, speech (rate and amount), language - thought disorder, content, disruptive - aggressive behavior, appearance, and insight. Each item had 5 or 9 grades of severity, with lower scores indicating milder symptoms. The number of raters within each trial center was to be kept to a minimum. The YMRS Total Score (range 0 to 44) is the sum of the rating scores for 11 items for assessing the core symptoms of mania. A missing value for any YMRS assessment item(s) could have resulted in a missing YMRS Total Score. A higher YMRS Total Score represents greater severity. In this study, 94 participants had bipolar disorder, this explains the N=94 in the table below and these were de novo participants.
Time frame: Baseline to Month 24
Mean Change From Baseline in Clinical Global Impression Scale - Bipolar (CGI-BP) Version Severity Score
The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rated the subject's Severity of Illness (CGI-BP-Severity: mania, depression, and overall bipolar illness) and Change From Preceding Phase (CGI-BP-Improvement: mania, depression, and overall bipolar illness) based on a 7- or 8-point scale. Severity of Illness (CGI-BP-Severity) was rated at all visits. At each visit other than Day 0 (Baseline), the Change From Preceding Phase (CGI-BP-Improvement) was judged with respect to participant's condition at Baseline. The CGI-BP Severity Scores (range 1 to 7), as well as CGI-BP Improvement Scores (range 1 to 7) are single-item rating scores, with higher scores representing greater severity or less improvement. Data for 94 de novo participants were available with bipolar disorder.
Time frame: Baseline to Month 24
Mean Change From Baseline in Clinical Global Impression Scale - Bipolar Version Improvement Score
The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rated the subject's Severity of Illness (CGI-BP-Severity: mania, depression, and overall bipolar illness) and Change From Preceding Phase (CGI-BP-Improvement: mania, depression, and overall bipolar illness) based on a 7- or 8-point scale. Severity of Illness (CGI-BP-Severity) was rated at all visits. At each visit other than Day 0 (Baseline), the Change From Preceding Phase (CGI-BP-Improvement) was judged with respect to participant's condition at Baseline. The CGI-BP Severity Scores (range 1 to 7), as well as CGI-BP Improvement Scores (range 1 to 7) are single-item rating scores, with higher scores representing greater severity or less improvement. Only 94 participants had data at Baseline to explain the N=94 in the table below and these were de novo participants.
Time frame: Baseline to Month 24
Mean Change From Baseline in General Behavior Inventory (GBI) Scale Total Score for Mania and Depression in Both Parent/Guardian and Subject Version of the Scale
The GBI is a self-report inventory with 73 items focusing on mood-related behaviors, including depressive, hypomanic, and biphasic symptoms. For this trial, two 20-item subscales were utilized: one was completed by the parent/guardian or legal representative, as applicable for local laws, and the other was completed by the participant. Responses were given on a 4-point Likert scale, with 0 being never or hardly ever and 3 being very often or almost constantly. The GBI Total Score for mania (range 0 to 30) is the sum of scores for items 1 to 10 and the GBI Total Score for depression (range 0 to 30) is the sum of scores for items 11 to 20 in the GBI Parent/Guardian or Subject Version panel. Scores from the Parent/Guardian and participant Versions were summarized separately. A missing value for any GBI assessment items could have resulted in a missing GBI Total Score. High scores represent greater psychopathology. Data was only available for 80 de novo participants with bipolar disorder.
Time frame: Baseline to Month 24
Mean Change From Baseline in the Attention Deficit Hyperactive Disorders Rating (ADHD-RS-IV) Scale Score
The ADHD-RS-IV is a reliable and easy-to-administer instrument both for diagnosing ADHD in children and adolescents and for assessing treatment response. Containing 18 items, the scale was linked directly to DSM-IV-TR diagnostic criteria for ADHD. There were 3 versions of the scale: a parent questionnaire on home behaviors (English), a parent questionnaire on home behaviors (Spanish), and a teacher questionnaire on classroom behaviors. For this trial, the parent questionnaire on home behaviors (English) was utilized. The ADHD-RS-IV Total Score (range 0 to 54) is the sum of rating scores for 18 items, with higher scores representing greater severity. A missing value for any ADHD-RS-IV assessment items could have resulted in a missing ADHD-RS-IV Total Score. Data were only available for 82 participants with bipolar disorder and these were de novo participants.
Time frame: Baseline to Month 24
Mean Change From Baseline in Children's Global Assessment Scale (CGAS) in Bipolar (de Novo Participants)
The CGAS is a 100-point rating scale measuring psychological, social, and school functioning for children aged 6 to 17. It was adapted from the Adults Global Assessment Scale. The Global Assessment Scale was a rating scale for evaluating the overall functioning of a participant during a specified time period on a continuum from psychological or psychiatric sickness to health. The CGAS is a valid and reliable tool for rating a child's general level of functioning on a health-illness continuum. The CGAS was developed by Schaffer and colleagues to provide a global measure of severity of disturbance in children and adolescents. The CGAS Score (range 1 to 100) is a single-item score for rating a child's general level of functioning on a health-illness continuum, with higher scores representing better functioning.
Time frame: Baseline to Month 24
This trial was conducted in 524 participants at 118 trial sites in the following 13 countries: Bulgaria, Croatia, Hungary, India, Malaysia, Philippines, Poland, Romania, Russia, Serbia, Taiwan, Ukraine, and the United States.
| Milestone | Conversion Phase | Open-label Treatment Phase |
|---|---|---|
| Started | 297 | 0 |
| Completed | 283 | 0 |
| Not completed | 14 | 0 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Met withdrawal criteria | 1 | 0 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Withdrawal by subject | 7 | 0 |
| Withdrew: Protocol deviation | 1 | 0 |
| Milestone | Conversion Phase | Open-label Treatment Phase |
|---|---|---|
| Started | 0 | 510 |
| Completed | 0 | 198 |
| Not completed | 0 | 312 |
| Withdrew: Lost to follow-up | 0 | 21 |
| Withdrew: Adverse event | 0 | 33 |
| Withdrew: Sponsor discontinued trial | 0 | 165 |
| Withdrew: Met withdrawal criteria | 0 | 9 |
| Withdrew: Physician decision | 0 | 12 |
| Withdrew: Withdrawal by subject | 0 | 65 |
| Withdrew: Lack of efficacy | 0 | 7 |
An AE was defined as any untoward medical occurrence in a participant or participant enrolled in a clinical trial and which did not necessarily have a causal relationship with the study medication. A treatment emergent adverse event (TEAE) was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study medication, whether or not considered to have a causal relationship with the study medication. A serious-AE or reaction was any untoward occurrence that, at any dose, was fatal, life-threatening, required inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was any other medically significant event that, based on appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the outcomes listed above.
| Participants | Open-label Treatment Phase |
|---|---|
| Participants with TEAEs | 349 |
| Participants with serious TEAEs | 49 |
| Participants with severe TEAEs | 33 |
| Discontinued due to AEs | 32 |
The laboratory values were one of the parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria. Abnormal laboratory values in participants were reported as SAE/AEs and are reported in the SAE/other AE section of this report.
| participants | Open-label Treatment Phase |
|---|---|
| Chemistry-Alanine transaminase | 11 |
| Chemistry-Aspartate transaminase | 8 |
| Chemistry-Bilirubin, total | 20 |
| Chemistry-Calcium | 30 |
| Chemistry-Chloride | 158 |
| Chemistry-Cholesterol, total, fasting | 68 |
| Chemistry-Creatine phosphokinase, total | 40 |
| Chemistry-Glutamyl transferase | 78 |
| Chemistry-HDL cholesterol, fasting | 128 |
| Chemistry-LDL cholesterol, calculation, | 2 |
| Chemistry-Phosphorus inorganic | 135 |
| Chemistry-Protein, total serum | 81 |
| Chemistry-Triglycerides, fasting | 46 |
| Hematology-Eosinophils | 19 |
| Hematology-Hemoglobin | 14 |
| Hematology-White blood cell count | 9 |
| Urinalysis-Protein, urine | 348 |
| Urinalysis-Specific gravity | 188 |
| Others-Insulin | 49 |
| Others-Insulin, fasting | 78 |
| Others-Prolactin | 324 |
The physical examination evaluation was one of the parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in the following body systems: head, ears, eyes, nose, and throat; thorax; abdomen; urogenital; extremities; neurological; and skin and mucosae.
| participants | Open-label Treatment Phase |
|---|---|
| Incidence of Physical Examination Findings of Potential Clinical Relevance | 0 |
Vital signs are taken at Baseline, Weeks 1, 2, 3, 4, 6, 8, and Months 3, 4, 6, 9, 12, 15, 18, 21, 24 of Phase 2 (Visits beyond Month 12 only for de novo subjects). Assessments included orthostatic (supine and standing) blood pressure (BP), heart rate and body temperature. Incidence of TEAEs of potential clinical relevance included abnormal values in heart rate, systolic and diastolic blood pressure, respiratory rate and weight that were identified based on pre-defined criteria. Abnormal vital signs in participants were reported as SAE/AEs and are reported in the SAE/other AE section of this report.
| participants | Open-label Treatment Phase |
|---|---|
| Heart rate supine-Increase ≥15 bpm | 1 |
| Heart rate supine-Decrease ≥15 bpm | 1 |
| Heart rate standing-Increase ≥15 bpm | 4 |
| Heart rate standing-Decrease ≥15 bpm | 0 |
| Systolic supine bp-Increase ≥20 mmHg | 36 |
| Systolic supine bp-Decrease ≥20 mmHg | 31 |
| Systolic standing bp-Increase ≥20 mmHg | 38 |
| Systolic standing bp-Decrease ≥20 mmHg | 40 |
| Diastolic supine bp-Increase ≥15 mmHg | 41 |
| Diastolic supine bp-Decrease ≥15 mmHg | 19 |
| Diastolic standing bp-Increase ≥15 mmHg | 53 |
| Diastolic standing bp-Decrease ≥15 mmHg | 13 |
| Weight gain ≥7% | 195 |
| Weight loss ≥7% | 45 |
The AIMS Scale was an extrapyramidal symptoms (EPS) rating scale. The AIMS is a 12 item scale. The first 10 items e.g. facial and oral movements (items 1-4), extremity movements (items 5 and 6), trunk movements (item 7), investigators global assessment of dyskinesia (items 8 to 10). The first 10 items are rated from 0 to 4 (0=best, 4=worst). Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28.
| Units on a scale | Open-label Treatment Phase |
|---|---|
| Week 1 (N=486) | -0.02 ± 0.24 |
| Week 2 (N=507) | -0.01 ± 0.25 |
| Week 3 (N=507) | 0.01 ± 0.36 |
| Week 4 (N=507) | -0.01 ± 0.27 |
| Week 6 (N=507) | 0.02 ± 0.56 |
| Week 8 (N=507) | -0.02 ± 0.28 |
| Month 3 (N=507) | -0.00 ± 0.31 |
| Month 6 (N=507) | -0.02 ± 0.40 |
| Month 9 (N=506) | 0.01 ± 0.55 |
| Month 12 (N=507) | -0.02 ± 0.41 |
| Month 15 (N=360) | -0.01 ± 0.43 |
| Month 18 (N=360) | -0.04 ± 0.35 |
| Month 21 (N=360) | -0.01 ± 0.52 |
| Month 24 (N=360) | -0.04 ± 0.34 |
The SAS is a rating scale used to measure EPS. The SAS scale consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia), with each item rated from 0 to 4, with 0 being normal and 4 being the worst. The SAS Total score is sum of ratings for all 10 items, with possible Total scores from 0 to 40.
| Units on a scale | Open-label Treatment Phase |
|---|---|
| Week 1 (N=486) | -0.08 ± 0.89 |
| Week 2 (N=507) | -0.11 ± 1.22 |
| Week 3 (N=507) | -0.08 ± 1.23 |
| Week 4 (N=507) | -0.18 ± 1.37 |
| Week 6 (N=507) | -0.12 ± 1.49 |
| Week 8 (N=507) | -0.21 ± 1.34 |
| Month 3 (N=507) | -0.23 ± 1.56 |
| Month 6 (N=507) | -0.31 ± 1.48 |
| Month 9 (N=506) | -0.35 ± 1.50 |
| Month 12 (N=507) | -0.36 ± 1.51 |
| Month 15 (N=360) | -0.43 ± 1.78 |
| Month 18 (N=360) | -0.48 ± 1.74 |
| Month 21 (N=360) | -0.49 ± 1.82 |
| Month 24 (N=360) | -0.53 ± 1.81 |
The BARS was an EPS rating scale. The BARS was used to assess the presence and severity of akathisia. This scale consists of 4 items. Only the 4th item, the Global Clinical Assessment of Akathisia, was evaluated in this trial. This item is rated on a 6 point scale, with 0 being best (absent) and 5 being worst (severe akathisia).
| Units on a scale | Open-label Treatment Phase |
|---|---|
| Week 1 (N=487) | -0.02 ± 0.26 |
| Week 2 (N=507) | -0.02 ± 0.35 |
| Week 3 (N=507) | -0.02 ± 0.35 |
| Week 4 (N=507) | -0.03 ± 0.33 |
| Week 6 (N=507) | -0.03 ± 0.36 |
| Week 8 (N=507) | -0.02 ± 0.41 |
| Month 3 (N=507) | -0.00 ± 0.45 |
| Month 6 (N=507) | -0.03 ± 0.44 |
| Month 9 (N=506) | -0.04 ± 0.43 |
| Month 12 (N=507) | -0.04 ± 0.42 |
| Month 15 (N=360) | -0.02 ± 0.47 |
| Month 18 (N=360) | -0.05 ± 0.48 |
| Month 21 (N=360) | -0.04 ± 0.50 |
| Month 24 (N=360) | -0.05 ± 0.47 |
The NY-AACENT is not a validated scale. It was included in this trial because of concerns that regulatory authorities (the European Committee for Medicinal Products for Human Use \[CHMP\] and the Paediatric Sub-Committee of the European Medicinal Agency \[PDCO\]) had regarding drug induced cognitive impairment. No validated scale addressing these issues was available at the time of the trial. The NY-AACENT was used to detect changes in cognitive function subsequent to pharmacological or similar treatments for neurological or psychiatric problems. It was specifically designed to be used in pediatric populations (ages 12 to 17), but could have been utilized with other age groups, as appropriate.
| participants | Open-label Treatment Phase |
|---|---|
| Working memory | 237 |
| Attention/vigilance | 306 |
| Verbal learning/memory | 233 |
| Visual learning/memory | 138 |
| Reasoning and problem solving | 308 |
| Speed of processing | 276 |
| Social congnition | 307 |
Tanner staging was completed together with the physical examination by the same trial-affiliated clinician in the most inconspicuous manner for the participant as possible. Tanner staging assessment consisted of 2 domains (pubic hair and breast development) for girls and 3 domains (pubic hair, penis development, and testes development) for boys. A participant who reached Stage 5 (both in pubic hair and genitalia) did not need to continue with Tanner Staging assessment and the Tanner Staging scales of this participant were imputed as 5 for all of the following scheduled time points up to and including the completion visit/ET visit. The clinician arrived at a single score summarizing the domains (not individual domain scores) when evaluating the participant. The total shift data for last visit is presented below.
| participants | Tanner Score at Baseline of 1 | Tanner Score at Baseline of 2 | Tanner Score at Baseline of 3 | Tanner Score at Baseline of 4 | Tanner Score at Baseline of 5 |
|---|---|---|---|---|---|
| Last Visit (Post-Baseline score of 1) (N= 1) | 1 | 0 | 0 | 0 | 0 |
| Last Visit (Post-Baseline score of 2) (N= 9) | 4 | 5 | 0 | 0 | 0 |
| Last Visit (Post-Baseline score of 3) (N= 39) | 2 | 9 | 28 | 0 | 0 |
| Last Visit (Post-Baseline score of 4) (N= 134) | 0 | 7 | 33 | 94 | 0 |
| Last Visit (Post-Baseline score of 5) (N= 327) | 0 | 3 | 18 | 102 | 204 |
Suicidality was defined as reporting at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any type of suicidal behaviors (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). Suicidal ideation was defined as reporting any type of suicidal ideation. The suicidal ideation intensity total score is the sum of intensity scores of 5 items (frequency, duration, controllability, deterrents, and reasons for ideation). The score of each intensity item ranges from 0 (none) to 5 (worst) which leads to the range of the total score from 0 to 25. A missing score of any item resulted in a missing total score. If no suicidal ideation was reported, a score of 0 was given to the intensity scale.
| Units on a scale | Open-label Treatment Phase |
|---|---|
| Week 1 (N= 487) | -0.4 ± 2.1 |
| Week 2 (N= 483) | -0.4 ± 2.2 |
| Week 3 (N= 477) | -0.4 ± 2.2 |
| Week 4 (N= 491) | -0.4 ± 2.2 |
| Week 6 (N= 488) | -0.3 ± 2.1 |
| Week 8 (N= 484) | -0.4 ± 2.0 |
| Month 3 (N= 478) | -0.3 ± 2.2 |
| Month 4 (N= 472) | -0.3 ± 2.1 |
| Month 6 (N= 458) | -0.2 ± 2.5 |
| Month 9 (N= 407) | -0.2 ± 1.8 |
| Month 12 (N= 302) | -0.3 ± 2.0 |
| Month 15 (N= 261) | -0.2 ± 1.9 |
| Month 18 (N= 247) | -0.1 ± 2.0 |
| Month 21 (N= 212) | -0.1 ± 1.8 |
| Month 24 (N= 180) | -0.0 ± 1.9 |
| Last Visit (N= 507) | -0.1 ± 2.5 |
Suicidality was defined as reporting at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any type of suicidal behaviors (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). Suicidal ideation was defined as reporting any type of suicidal ideation. The below reported N value is the number of participants with specified suicidal ideation/behavior at the given time point.
| participants | Open-label Treatment Phase |
|---|---|
| Complete suicidality | 0 |
| Suicidality | 32 |
| Suicidal behavior | 5 |
| Emergence of suicidal behavior | 3 |
| Suicidal ideation | 31 |
| Emergence of suicidal ideation | 19 |
| Emergence of serious suicial ideation | 2 |
| Worsening of suicidal ideation | 26 |
The percentage of participants who discontinued due to all causes other than sponsor terminating the trial was measured from the date of entering the open-label treatment phase to the date of ET for discontinued participants in the open-label treatment phase (ie, time to discontinuation = date of discontinuation \[or date of completion for completed participants\] - date of participant entering the open-label treatment phase + 1). If the participants completed the trial or were discontinued due to the sponsor terminating the trial, they were censored at the time of completion or trial termination, respectively.
| percentage of participants | Open-label Treatment Phase |
|---|---|
| From study NCT01149655 (N= 148) | 3.4 |
| De Novo (N= 362) | 7.7 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
| Units on a scale | Open-label Treatment Phase |
|---|---|
| Month 12 (N= 414) | -9.98 ± 14.66 |
| Month 24 (N= 267) | -12.52 ± 15.70 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).
| Units on a scale | Open-label Treatment Phase |
|---|---|
| Month 12 (N= 414) | -2.57 ± 4.96 |
| Month 24 (N= 267) | -2.91 ± 5.13 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).
| Units on a scale | Open-label Treatment Phase |
|---|---|
| Month 12 (N= 414) | -2.79 ± 4.17 |
| Month 24 (N= 267) | -3.48 ± 4.63 |
The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
| Units on a scale | Open-label Treatment Phase |
|---|---|
| Month 12 (N= 414) | -0.66 ± 0.96 |
| Month 24 (N= 267) | -0.77 ± 1.04 |
The efficacy of trial medication were rated for each participant using the CGI-I scale. The study physician must rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at baseline. Response choices include: 0 = not assessed; 1 =very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 =minimally worse; 6 = much worse; and 7 = very much worse.
| Units on a scale | Open-label Treatment Phase |
|---|---|
| Month 12 (N= 408) | 2.62 ± 1.16 |
| Month 24 (N= 263) | 2.38 ± 1.15 |
The YMRS consists of 11 items assessing the core symptoms of mania and was used to assess participants with bipolar I disorder, manic and mixed episodes with or without psychotic features: elevated mood, increased motor activity - energy, sexual interest, sleep, irritability, speech (rate and amount), language - thought disorder, content, disruptive - aggressive behavior, appearance, and insight. Each item had 5 or 9 grades of severity, with lower scores indicating milder symptoms. The number of raters within each trial center was to be kept to a minimum. The YMRS Total Score (range 0 to 44) is the sum of the rating scores for 11 items for assessing the core symptoms of mania. A missing value for any YMRS assessment item(s) could have resulted in a missing YMRS Total Score. A higher YMRS Total Score represents greater severity. In this study, 94 participants had bipolar disorder, this explains the N=94 in the table below and these were de novo participants.
| Units on a scale | Open-label Treatment Phase |
|---|---|
| Month 12 (N= 93) | -9.71 ± 10.23 |
| Month 24 (N= 93) | -10.02 ± 10.21 |
The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rated the subject's Severity of Illness (CGI-BP-Severity: mania, depression, and overall bipolar illness) and Change From Preceding Phase (CGI-BP-Improvement: mania, depression, and overall bipolar illness) based on a 7- or 8-point scale. Severity of Illness (CGI-BP-Severity) was rated at all visits. At each visit other than Day 0 (Baseline), the Change From Preceding Phase (CGI-BP-Improvement) was judged with respect to participant's condition at Baseline. The CGI-BP Severity Scores (range 1 to 7), as well as CGI-BP Improvement Scores (range 1 to 7) are single-item rating scores, with higher scores representing greater severity or less improvement. Data for 94 de novo participants were available with bipolar disorder.
| Units on a scale | Open-label Treatment Phase |
|---|---|
| Month 12 (N= 93) | -1.26 ± 1.33 |
| Month 24 (N= 93) | -1.30 ± 1.37 |
The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rated the subject's Severity of Illness (CGI-BP-Severity: mania, depression, and overall bipolar illness) and Change From Preceding Phase (CGI-BP-Improvement: mania, depression, and overall bipolar illness) based on a 7- or 8-point scale. Severity of Illness (CGI-BP-Severity) was rated at all visits. At each visit other than Day 0 (Baseline), the Change From Preceding Phase (CGI-BP-Improvement) was judged with respect to participant's condition at Baseline. The CGI-BP Severity Scores (range 1 to 7), as well as CGI-BP Improvement Scores (range 1 to 7) are single-item rating scores, with higher scores representing greater severity or less improvement. Only 94 participants had data at Baseline to explain the N=94 in the table below and these were de novo participants.
| Units on a scale | Open-label Treatment Phase |
|---|---|
| Month 12 (N= 93) | 2.27 ± 1.28 |
| Month 24 (N= 93) | 2.17 ± 1.27 |
The GBI is a self-report inventory with 73 items focusing on mood-related behaviors, including depressive, hypomanic, and biphasic symptoms. For this trial, two 20-item subscales were utilized: one was completed by the parent/guardian or legal representative, as applicable for local laws, and the other was completed by the participant. Responses were given on a 4-point Likert scale, with 0 being never or hardly ever and 3 being very often or almost constantly. The GBI Total Score for mania (range 0 to 30) is the sum of scores for items 1 to 10 and the GBI Total Score for depression (range 0 to 30) is the sum of scores for items 11 to 20 in the GBI Parent/Guardian or Subject Version panel. Scores from the Parent/Guardian and participant Versions were summarized separately. A missing value for any GBI assessment items could have resulted in a missing GBI Total Score. High scores represent greater psychopathology. Data was only available for 80 de novo participants with bipolar disorder.
| Units on a scale | Open-label Treatment Phase |
|---|---|
| Month 12 (N= 78) | -1.62 ± 7.20 |
| Month 24 (N= 78) | -1.82 ± 7.37 |
The ADHD-RS-IV is a reliable and easy-to-administer instrument both for diagnosing ADHD in children and adolescents and for assessing treatment response. Containing 18 items, the scale was linked directly to DSM-IV-TR diagnostic criteria for ADHD. There were 3 versions of the scale: a parent questionnaire on home behaviors (English), a parent questionnaire on home behaviors (Spanish), and a teacher questionnaire on classroom behaviors. For this trial, the parent questionnaire on home behaviors (English) was utilized. The ADHD-RS-IV Total Score (range 0 to 54) is the sum of rating scores for 18 items, with higher scores representing greater severity. A missing value for any ADHD-RS-IV assessment items could have resulted in a missing ADHD-RS-IV Total Score. Data were only available for 82 participants with bipolar disorder and these were de novo participants.
| Units on a scale | Open-label Treatment Phase |
|---|---|
| Month 12 (N= 81) | -3.25 ± 10.43 |
| Month 24 (N= 81) | -2.53 ± 10.73 |
The CGAS is a 100-point rating scale measuring psychological, social, and school functioning for children aged 6 to 17. It was adapted from the Adults Global Assessment Scale. The Global Assessment Scale was a rating scale for evaluating the overall functioning of a participant during a specified time period on a continuum from psychological or psychiatric sickness to health. The CGAS is a valid and reliable tool for rating a child's general level of functioning on a health-illness continuum. The CGAS was developed by Schaffer and colleagues to provide a global measure of severity of disturbance in children and adolescents. The CGAS Score (range 1 to 100) is a single-item score for rating a child's general level of functioning on a health-illness continuum, with higher scores representing better functioning.
| Units on a scale | Open-label Treatment Phase |
|---|---|
| Month 12 (N= 93) | 14.17 ± 16.01 |
| Month 24 (N= 93) | 14.00 ± 16.23 |
Collected over Adverse events were reported from the signing of the informed consent, during the 24-month treatment period until the follow-up visit 30 (± 3) days after the end of trial.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Conversion Phase | — | 2/297 (0.7%) | 40/297 (13.5%) |
| Open-label Treatment Phase | — | 49/510 (9.6%) | 194/510 (38%) |
| Event | Conversion Phase | Open-label Treatment Phase |
|---|---|---|
| SchizophreniaPsychiatric disorders | 0/297 | 18/510 |
| Suicidal ideationPsychiatric disorders | 0/297 | 8/510 |
| Bipolar disorderPsychiatric disorders | 0/297 | 7/510 |
| AggressionPsychiatric disorders | 0/297 | 3/510 |
| AgitationPsychiatric disorders | 0/297 | 3/510 |
| Hallucination, auditoryPsychiatric disorders | 0/297 | 2/510 |
| Suicide attemptPsychiatric disorders | 0/297 | 2/510 |
| Bipolar I disorderPsychiatric disorders | 1/297 | 1/510 |
| Tooth disorderGastrointestinal disorders | 1/297 | 0/510 |
| Gilbert's syndromeCongenital, familial and genetic disorders | 0/297 | 1/510 |
| Event | Conversion Phase | Open-label Treatment Phase |
|---|---|---|
| HeadacheNervous system disorders | 23/297 | 67/510 |
| Weight increasedInvestigations | 1/297 | 38/510 |
| SomnolenceNervous system disorders | 20/297 | 33/510 |
| NasopharyngitisInfections and infestations | 5/297 | 34/510 |
| AnxietyPsychiatric disorders | 6/297 | 32/510 |
| VomitingGastrointestinal disorders | 4/297 | 30/510 |
| SchizophreniaPsychiatric disorders | 1/297 | 30/510 |
| Age, Continuous(Years) | All Study Participants |
|---|---|
| Mean | 15.2 ± 1.6 |
| Sex: Female, Male(Participants) | All Study Participants |
|---|---|
| Female | 316 |
| Male | 208 |
Showing the first 100 of 101 sites across 13 countries. Choose a country and city above to see the rest.
The record gives a start of Jul 2010, a primary completion of Aug 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →